** Shares of Organovo Holdings ONVO.O more than tripled to $1.35 premarket
** ONVO says it is selling its FXR program, including lead asset FXR314, to Eli Lilly LLY.N
** ONVO's FXR program is focused on developing novel treatment approaches for inflammatory bowel disease
** LLY will pay ONVO $10 mln upfront and $50 mln if certain milestones are met in future, according to agreement
** LLY is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development
** Acquisition will allow Eli Lilly to further develop FXR314, starting from mid-stage, ONVO says
** ONVO fell ~68% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.